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Staphylococcus aureusAlthough Staphylococcus aureus is a prominent cause of infections, no vaccine is currently available. Active
vaccination relies on immune memory, a core competence of the adaptive immune system.
To elucidatewhether adaptive immunity can provide protection from serious complications of S. aureus infection,
a prospective observational study of 44 patientswith S. aureus infection complicated by bacteremiawas conduct-
ed. At diagnosis, serum IgG binding to S. aureus extracellular proteins was quantiﬁed on immunoblots and with
Luminex-based FLEXMAP 3D™ assays comprising 64 recombinant S. aureus proteins. Results were correlated
with the course of the infection with sepsis as the main outcome variable.
S. aureus-speciﬁc serum IgG levels at diagnosis of S. aureus infection were lower in patients developing sepsis
than in patients without sepsis (P b 0.05). The pattern of IgG binding to eight selected S. aureus proteins correctly
predicted the disease course in 75% of patients.
Robust immune memory of S. aureus was associated with protection from serious complications of bacterial
invasion. Serum IgG binding to eight conserved S. aureus proteins enabled stratiﬁcation of patients with high
and low risk of sepsis early in the course of S. aureus infections complicated by bacteremia.
Signiﬁcance: S. aureus is a dangerous pathogen of ever increasing importance both in hospitals and in the commu-
nity. Due to the crisis of antibiotic resistance, an urgent need exists for new strategies to combat S. aureus
infections, such as vaccination. To date, however, all vaccine trials have failed in clinical studies. It is therefore
unclear whether the adaptive immune system is at all able to control S. aureus in humans.
The paper demonstrates the use of proteomics for providing an answer to this crucial question. It describes novel
results of a prospective study in patients with S. aureus infection complicated by bloodstream invasion. Immune
proteomic analysis shows that robust immune memory of S. aureus – reﬂected by strong serum IgG antibody
binding to S. aureus antigens – is associated with clinical protection from sepsis. This lends support to the notion
of a vaccine to protect against the most serious complications of S. aureus infection. Hence, the data encourage
further efforts in vaccine development.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Staphylococcus aureus is a serious pathogen in both hospitals and the
community, but also a common commensal [1–3]. In spite of intensivegie und Transfusionsmedizin,
straße/DZ7, 17475 Greifswald,
er).
. This is an open access article underefforts, there is no vaccine to protect against S. aureus infections [4,5].
Active vaccination strategies rely on immune memory, a core compe-
tence of the adaptive immune system, comprised of T cells, B cells and
antibodies. This raises the question of what the adaptive immune
system can contribute to protection against S. aureus.
Both S. aureus carriers (around 20% of adults) as well as non-carriers
harbor serum antibodies speciﬁc for a broad spectrum of S. aureus pro-
teins and non-protein antigens [6,7]. Clearly, encounters of S. aureus
with its humanhost donot lead to sterile immunity, nor do they preventthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Comparison of the characteristics of immune-competent, hospitalized adults with a max-
imum of 4 days of symptoms at the time of S. aureus bacteremia by the development of
sepsis.
Sepsis
(n = 19)
No sepsis
(n = 21)
Odds ratioa
(CI)
P-value
Demographics
Mean age (±SD) 59 ± 13 57 ± 18 0.75
Gender 0.99
(0.29–3.43)
1.0
Female 9 10
Male 10 10
Race 0.63
African American 11 15
White 7 6
Unanswered 1 2
Prior S. aureus infection 1.52 (CI 0.34
to 6.76)
0.71
Yes 5 4
No 14 17
Prior MRSA infection or
colonization
0.71
Yes 7 6
No 10 11
No data 2 4
Dialysis patient 0.48 (CI 0.12
to 1.81)
0.33
Yes 5 9
No 14 12
Diabetes mellitus patient 0.53 (CI 0.13
to 2.23)
0.49
Yes 4 7
No 15 14
Infection Characteristics
Bacteremia type (primary?) 5.23 (CI 0.95
to 28.9)
0.069
Primary 17 13
Secondary 2 8
If secondary bacteremia, type 1.0 (CI 0.03
to 33.4)
1.0
SSTI 2 7
UTI 0 1
Nosocomial infection 2.31 (CI 0.56
to 9.47)
0.31
Yes 15 13
No 4 8
Current MRSAb 0.46 (CI 0.12
to 1.79)
0.32
Yes 11 15
No 8 5
Days since presentation of
symptoms
0.9 ± 0.3
(n = 18)
1.3 ± 0.3 0.35
Abbreviations: CI, conﬁdence interval; MRSA, methicillin-resistant S. aureus; SD, standard
deviation; SSTI skin and soft tissue infection; UTI, urinary tract infection.
a Odds ratio for sepsis development.
b Reﬂects the current infection isolate. Data of one non-septic patient were missing.
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infection mostly with their colonizing strain [1,8].
However, there are indications that the adaptive immune system
may confer clinical protection against severe S. aureus infection. First,
S. aureus bloodstream infection has a better outcome in carriers than
in non-carriers, which could be due to the generation of strain-speciﬁc
immune memory during colonization [9,10]. Moreover, functional
defects of adaptive immunity increase the risk of severe S. aureus infec-
tion in humans and animal models. The Th17 T cell subpopulation is
currently receiving much attention in this context [11–15]. Finally,
good protection has been achieved in animal models with active and
passive vaccines targeting a variety of S. aureus proteins [16,17].
The natural human antibody response to S. aureus is characterized
by pronounced heterogeneity [6,18], reﬂecting the immune memory
formed during an individual's encounters with S. aureus. We hypothe-
sized that upon bacterial invasion, immune memory of S. aureus will
confer clinical protection, and the S. aureus-speciﬁc antibody response
might permit patient stratiﬁcation. To test this hypothesis, we conduct-
ed a prospective observational study with 44 patients diagnosed with
S. aureus infection complicated by bacteremia.
2. Patients, materials and methods
2.1. Clinical study design
In a prospective observational study, sera from a convenience sam-
ple of patients with S. aureus infection complicated by bacteremia
were collected at diagnosis as previously described [19]. Human exper-
imentation guidelines of the United States Department of Health and
Human Services and those of the authors' institution(s) were followed
while performing of clinical research. The study was approved by the
University of Maryland Baltimore Institutional Review Board and was
granted a waiver of informed consent. Patients with AIDS, severe im-
mune suppression other than AIDS and symptoms of infection more
than 4 days prior to infection presentation were excluded. Patients
were monitored for three days after the ﬁrst positive blood culture for
the presence or development of sepsis. The outcome criteria for uncom-
plicated sepsis, severe sepsis and septic shock were adapted from the
American College of Chest Physicians and Society for Critical Care
Medicine deﬁnition [20]. Other variables shown in Table 1 were
abstracted from the medical record.
2.2. S. aureus isolates, protein extracts and bacterial cell preparations
Infecting S. aureus isolates were molecularly typed based on their
spa-sequences, and virulence genes encoding superantigens, exfoliative
toxins, as well as PVL were identiﬁed bymultiplex-PCR [21]. Extracellu-
lar protein extracts were obtained from a protein A gene (spa) deletion
mutant of S. aureus USA300 (USA300Δspa) cultivated to stationary
phase under iron-restricted conditions [22]. Whole bacterial cells were
washed and UV-inactivated. Recombinant S. aureus proteins were
obtained from Protagen AG (Dortmund, Germany).
2.3. Quantiﬁcation of serum IgG binding to S. aureus
Serum IgG binding to extracellular bacterial protein extracts was
quantiﬁed by semi-automated immunoblotting (Peggy Simple Western
Assay). Binding to the S. aureus cell surface was determined by ELISA.
Finally, serum IgG speciﬁc to 64 recombinant S. aureus proteins wasmea-
sured using FLEXMAP3D™ technology, and normalizedmeanﬂuorescent
intensities were calculated as measures of antibody binding intensity.
2.4. Data analysis and statistics
Binding data obtained with immunoblot or ELISA were compared
using the Mann–Whitney test (two groups) or the Kruskal–Wallis testwith Dunn's post-test (more than two groups). P-values below 0.05
were considered statistically signiﬁcant. Principle component analysis
(PCA), partial least square analysis (PLS) and prediction analysis of
the FLEXMAP 3D™ data were performed using the Analyst Software
(Genedata, Basel, Switzerland).
The supporting information contains additional details about
patients, materials and methods.3. Results
3.1. Infecting S. aureus isolates
Of the 44 infecting S. aureus isolates, 14 (35%) belonged to the spa
type t008 and most of these were further characterized by agr type 1,
pvl and the superantigen gene seq, indicating that these strains repre-
sent USA300 strains. The remaining isolates were of mixed spa types
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exfoliative toxins encoding genes eta or etd (Table S1).
3.2. Serum IgG binding to S. aureus cells or extracellular proteins
USA300, themost frequent cause of bloodstream invasion in this co-
hort, was selected for quantiﬁcation of S. aureus-speciﬁc serum IgG. A
protein-A gene deletion mutant, USA300Δspa, was generated to avoid
non-speciﬁc antibody binding. Patient sera were obtained at diagnosis,
no later than four days after onset of symptoms, and IgG binding to ex-
tracellular bacterial proteins was measured (n= 46). Total IgG binding
varied by a factor of 27 (range: 65140–1763988 AUC, Fig. 1A). Patients
who subsequently developed sepsis – uncomplicated sepsis, severe sep-
sis or septic shock – showed lower IgG binding to S. aureus extracellular
proteins (P = 0.0481, Fig. 1B). Moreover, IgG binding to extracellular
S. aureus proteins decreased with increasing sepsis severity (Fig. 1D).
On the other hand, 7 out of 11 patients in the lower quartile of the
antibody binding values developed sepsis, but only 3 out of 11 in the
upper quartile did so (Fig. 1E). Similarly, IgG binding to thebacterial sur-
face was lower in the sepsis group than in patients who remained
sepsis-free (P= 0.0409, Fig. 1C).
3.3. Serum IgG binding to selected S. aureus proteins
To identify antibody speciﬁcities associated with protection against
sepsis, IgG binding to 64 recombinant S. aureus proteins was measured,
comprising extra-cellular, surface bound and cytoplasmic S. aureus pro-
teins (Table S2). 44 sera were available for this analysis (sera obtained
before or at onset of symptoms). At ﬁrst, patients were grouped into
(i) no sepsis, (ii) uncomplicated sepsis, and (iii) severe sepsis or septic
shock and results were subjected to a partial least squares analysis
(PLS) (Fig. 2A). Patients with uncomplicated sepsis and severe sepsis/
septic shock clustered together in one area and were hence handled as
one group, “sepsis”, in a second PLS analysis. This resulted in a separa-
tion from patients without sepsis, as shown in Fig. 2B.
The top 20 S. aureus proteins responsible for the discrimination are
listed in Table 2. Almost all of these proteins belonged to theFig. 1. Association between S. aureus speciﬁc serum IgG and outcome of bacteremia. Binding o
determined by immunoblot – Peggy Simple Western Assay – and ELISA, respectively. At diag
(A). Patients with high amounts of S. aureus-speciﬁc IgG had a signiﬁcantly better disease outco
to S. aureus cells (C [P= 0.0409; Mann–Whitney]). Figures show medians with interquartile rextracellular proteome, which elicited the strongest antibody binding,
as expected (Fig. 3). They included known toxins and virulence factors
of S. aureus and also proteins of unknown function. Further analysis
with a support vector machine revealed the best discrimination be-
tween patients with and without sepsis by applying Fisher linear dis-
criminant analysis to the intensities of IgG binding to the top 8
proteins: phospholipase C (Plc), staphopain B (SspB), the
immunodominant staphylococcal protein A (IsaA), the staphylococcal
exotoxin M (SEM), glycerophosphoryl diester phophodiesterase
(GlpQ), theC component ofγ-hemolysin (HlgC) and twoproteins of un-
known function, SACOL0444 and SACOL0985. To validate this result, a
principal component analysis was performed with serum IgG binding
to the top 8 proteins upon diagnosis. The degree of separation of pa-
tients with and without subsequent sepsis is depicted in Fig. 2C. Sepsis
was correctly predicted by Fisher linear discriminant analysis in 16 of
21 cases and no sepsis in 17 out of 23 cases; thus, the prediction was
correct in 75% of the cases (sensitivity 76%; speciﬁcity 74%). IgG binding
to the top 8 proteins differed signiﬁcantly between patients who subse-
quently developed sepsis or no sepsis as depicted in Fig. 2D. However,
the two groups could not be separated on the basis of antibody binding
to single S. aureus proteins.
Details of the data analysis are provided in the supporting material.
4. Discussion
At diagnosis of S. aureus bloodstream infection, serum IgG binding to
the bacterial extracellular proteome was inversely correlated with the
risk of sepsis development. We observed an almost 30-fold variation
in total serum IgG binding to extracellular S. aureus proteins. Very
high S. aureus-speciﬁc IgG serum levels characterized a subgroup of pa-
tients who almost never experienced sepsis. The fate of patients with
medium to low intensity IgG binding was non-uniform. Antibody bind-
ing to extracellular S. aureus proteins and S. aureus cells discriminated
both groups equally well.
An immune proteome signature of eight S. aureus proteins predicted
the disease course of bacteremia patients with 75% accuracy (76%
sensitivity and 74% speciﬁcity). This proteomic signature was mainlyf IgG to extracellular S. aureus proteins (A, B, D and E) and whole S. aureus cells (C) was
nosis, binding of IgG to extracellular S. aureus proteins varied strongly between patients
me (B [P=0.0481; Mann–Whitney], D and E). This could also been shown for IgG binding
anges. Abbreviations: AUC, area under curve; AU, arbitrary units.
Fig. 2. Stratiﬁcation of patients according to disease progression (sepsis or uncomplicated recovery) based on S. aureus-speciﬁc antibodies. Quantiﬁcation of IgG speciﬁc to 64 S. aureus
proteinswas performedwith FLEXMAP 3D™ technology. Patientswith uncomplicated sepsis and severe sepsis or septic shock grouped together (as sepsis) in partial least squares analysis
(PLS) (A). PLS showed good separation of patients with sepsis – including uncomplicated sepsis, severe sepsis and septic shock – from patients with no sepsis (B). Using the eight most
discriminating S. aureusproteins for a principal component analysis (see also Table 2) enabled stratiﬁcation of septic and non-septic patients at diagnosis of S. aureus bloodstream invasion
(C). Differences of quantiﬁed median IgG binding to these eight proteins between septic and non-septic patients are shown in D.
4 S. Stentzel et al. / Journal of Proteomics 128 (2015) 1–7comprised of conserved extracellular S. aureus proteins:with the excep-
tion of the superantigen SEM, all belong to the S. aureus core genome
[23]. This was expected because patients were not stratiﬁed according
to the type of the infecting S. aureus isolate, and many S. aureus toxin
genes – such as those encoding superantigens and other toxins – are
highly variable in the species S. aureus, as are serum antibodies speciﬁc
to them [10,24]. Keeping in mind that the infecting S. aureus isolates in
the present study reﬂect the epidemiological situation in the US, the re-
sults should be regarded as a proof of concept. While the predictive
value of the described S. aureus signature antigens may not justify clin-
ical application, the results do provide impetus for the investigation of
larger patient cohorts from different geographical areas to either deﬁne
a universal immune proteome signature of protection against S. aureus
sepsis or to develop more specialized tests capturing the antigen
repertoire of invasive S. aureus in different regions of the world.
Although vaccine trials have not prevented S. aureus infection
[4,5,25], the results of this prospective study strengthen the caseof a protective role of the adaptive immune system in ameliorating
S. aureus infections. Speciﬁc serum IgG indicates immune memory of
S. aureus, a core competence of the adaptive immune system, which is
the basis of vaccination effects. It was clearly associatedwith protection
from septic complications of S. aureus bloodstream invasion. Remark-
ably, the association of S. aureus-speciﬁc serum IgG with a favorable
disease course was lost if sera were obtained later than 4 days after in-
fection presentation (data not shown). This suggests that the protection
from septic complications of S. aureus invasion was mainly provided by
pre-existing speciﬁc IgG or immunememory of S. aureus rather than by
the IgG response triggered by the current infection.
The ﬁndings corroborate previous observations: S. aureus carriers
have higher levels of speciﬁc antibodies than do non-carriers [6,18],
but a lowermortality rate in the case of S. aureusbacteremia [9]. Similar-
ly, patients with uncomplicated recovery from bloodstream infection
had higher antibody titers speciﬁc to S. aureus exotoxins at diagnosis
than did patients who developed sepsis [19]. Epidermolysis bullosa
Table 2
Top 20 S. aureus proteins for patient stratiﬁcation.
The eight most discriminating S. aureus proteins used in the principal component analysis are highlighted (see also Fig. 2C).
Abbreviation Description Gene locus GI–Number Protein localizationa
Psortb LocateP SignalP TM domain
Plc 1–Phosphatidylinositol phosphodiesterase SAUSA300_0099 87128097 Extracellular
N–terminally
anchored Yes 1
SspB Staphopain B SA0900 15926634 Extracellular Secretory Yes 1
IsaA Probable transglycosylase SAOUHSC_02887 88196515 Extracellular
N–terminally
anchored Yes 0
Uncharacterized protein SACOL0444 57652631
Cytoplasmic
Membrane Lipid anchored Yes 0
SEM Staphylococcal enterotoxin M SA1647 15927403 Extracellular
N–terminally
anchored Yes 0
Surface protein, putative SACOL0985 57650173
Cytoplasmic
Membrane
N–terminally
anchored Yes 0
GlpQ Glycerophosphoryl diester phosphodiesterase SAUSA300_0862 87126873 Extracellular
N–terminally
anchored Yes 0
HlgC Gamma–hemolysin component C SACOL2421 57650965 Extracellular Secretory Yes 0
SplB Serine protease SplB SAOUHSC_01941 88195635 Extracellular
N–terminally
anchored Yes 1
Sak Staphylokinase, putative SAOUHSC_02171 88195848 Extracellular Secretory Yes 0
Atl Bifunctional autolysin SAOUHSC_00994b 88194750 Extracellular Secretory Yes 0
Efb–c Fibrinogen–binding protein SAOUHSC_01114 88194860 Extracellular N–terminallyanchored Yes 0
Uncharacterized protein SACOL0480 57651321 CytoplasmicMembrane
N–terminally
anchored Yes 1
GreA Transcription elongation factor SA1438 15927190 Cytoplasmic Intracellular No 0
LukF–PV LukF–PV SAUSA300_1381 87126598 – – – –
TSST–1 Toxic shock syndrome toxin–1 SA1819 15927587 Extracellular Secretory Yes 1
HlgB Gamma–hemolysin component B SACOL2422 57650966 Extracellular Secretory Yes 0
Coa Coagulase SAOUHSC_00192 88194002 Extracellular Secretory Yes 0
Lip Triacylglycerol lipase 1 SAUSA300_2603 87126156 Extracellular N–terminallyanchored Yes 1
Uncharacterized protein SACOL0908 57651598 Cytoplasmic Membrane
N–terminally
anchored Yes 0
Abbreviations: TM, transmembrane.
aProtein localization was predicted with different algorithms using the Aureowiki database and S. aureus COL as reference strain
(http://www.protecs.uni-greifswald.de/aureowiki/Main_Page; November 2014).
bN-terminal part of the protein.
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show high serum concentrations of anti-staphylococcal antibodies and
do not usually develop systemic S. aureus infection [26]. Conversely,
children with low pre-existing IgG titers to S. aureus α-hemolysin and
Panton–Valentine leukocidinweremore prone to invasive S. aureus dis-
ease [27]. In summary, the literature agrees about a negative correlation
between speciﬁc antibodies and severity of S. aureus disease.
The present work extends this knowledge and indicates for the
ﬁrst time that patient stratiﬁcation based on S. aureus-speciﬁc anti-
bodies may be possible at diagnosis of S. aureus bloodstream inva-
sion. In particular, a subgroup of bacteremia patients with very
strong S. aureus-speciﬁc antibody binding rarely developed septic
complications. Such information may also be useful in clinical inter-
vention studies, such as active or passive S. aureus vaccination trials.
For this, a panel of eight S. aureus antigens identiﬁed among 64 test-
ed recombinant S. aureus antigens was instrumental. Encouragingly
– in contrast to earlier data reported from the same patient cohort
[19] – seven of these eight signature proteins belong to the con-
served S. aureus core genome. This made it unnecessary to ﬁlter pa-
tients according to the infecting S. aureus strain and will make it
easier to translate the ﬁndings into a diagnostic tool.Regarding the mechanisms of protection provided by the adaptive
immune system, there are several mutually non-exclusive possibilities
[28]. On the one hand, antibodies may opsonize the bacteria or neutral-
ize potent S. aureus virulence factors such as the pore-forming toxinsα-
toxin, PVL and LukE/LukF, as well as superantigens. On the other hand,
the antibodies might also be considered as a marker of S. aureus-
speciﬁc T cell memory, because most B cells require cognate (antigen-
speciﬁc) T cell help to generate antibodies, especially for performing a
class switch from IgM to other Ig subclasses. Besides help for B cells,
memory T cells could fulﬁll numerous functions in anti-bacterial de-
fense, e.g., they promote the maturation of neutrophils, their release
from the bone marrow and recruitment to the site of infection [28–30].
In summary, besides indicating the possibility of patient stratiﬁca-
tion according to their sepsis risk, our data lend support to the idea of
a vaccine to protect against the most serious complications of S. aureus
infection and encourage further efforts in this direction.
Transparency document
The Transparency document associated with this article can be
found, in online version.
Fig. 3. IgG binding to 64 recombinant S. aureus proteins. Proteins are grouped according to their predicted cellular location (see also Table S2) and function. Normalizedmedian serum IgG
binding intensity of all patients is expressed by a color code (Log2median of antibody binding intensity). Extra-cellular and surface-bound proteins were preferentially recognized by the
serum antibodies.
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